Foreign currency headwinds and declining sales of Rebif (interferon beta-1a) have done Merck KGAA no favors in Q2, but the German group hopes that the early promise shown by its newer multiple sclerosis drug Mavenclad (cladribine) will lead it back to growth.
Rebif sales came in at a respectable €383m for the quarter, falling by 4.2% organically but also hit by negative...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?